Samsung C&T (028260) investor relations material

Executive summary

• Q2 2026 sales reached KRW 11.995 trillion and operating profit was KRW 1.032 trillion, with operating margin at 8.6%.

• Sales and operating profit increased both sequentially and year-over-year, driven by E&C Hi-Tech projects, robust T&I trading, and Bio segment growth.

• Strategic investments and acquisitions in energy, data centers, and life sciences, including the acquisition of PolyPeptide and Human Genome Sciences, Inc.

• Major share retirements completed, reducing outstanding shares to 163.6 million.

• The group operates across construction, trading, fashion, resort, food service, and bio segments, with trading and construction as the largest contributors.

Financial highlights

• Q2 2026 consolidated sales were KRW 11.995 trillion, up KRW 1.973 trillion YoY and KRW 1.529 trillion sequentially; operating profit was KRW 1.032 trillion, up KRW 279 billion YoY and KRW 312 billion sequentially.

• Net profit for Q2 was KRW 916 billion; pre-tax profit at KRW 1.077 trillion.

• H1 2026 revenue was KRW 22.46 trillion, with operating income of KRW 1.75 trillion and net income of KRW 2.00 trillion.

• Total assets at end-Q2: KRW 163.769 trillion; total equity: KRW 113.709 trillion; debt decreased to KRW 3.087 trillion.

• Cash and cash equivalents increased to KRW 4.86 trillion.

Outlook and guidance

• Q3 sales and operating profit growth expected to continue, with further acceleration in H2 2026, especially in E&C Hi-Tech and Bio segments.

• T&I expects Q3 moderation due to commodity downturn and EU steel quotas, but aims for full-year diversification and margin improvement.

• Fashion and F&B to pursue earnings improvement for full year despite potential Q3 moderation.

• Dividend policy targets 60–70% of affiliate dividend income, with a minimum dividend per share raised to KRW 2,500.

• Management focuses on financial stability, investment in growth, and shareholder returns.